Sebazole (TM) is a topical formulation consisting of 2.0% ketoconazole, an antifungal agent, formulated in a waterless gel for once-daily application. The Company expects to enroll approximately 440 ...
LONDON (CBS.MW) -- Pharmaceutical Barrier Therapeutics btrx announced that results from its confirmatory Phase III clinical trial for Sebazole, designed to treat seborrheic dermatitis, were positive.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback